# Bunkerhill Health

> Bunkerhill Health is a San Francisco AI company building the 'system of action' for hospitals. Its Carebricks platform lets health systems create, share, and deploy AI agents that turn routine data - especially CT scans already sitting in the archive - into actionable clinical findings. Born out of Stanford's Center for AI in Medicine and Imaging, the company has racked up a string of first-in-class FDA clearances for opportunistic detection of cardiovascular and bone disease, and in 2026 secured a national CMS reimbursement pathway for AI cardiovascular analysis.

- **Founded:** 2018
- **Headquarters:** San Francisco, United States
- **Founders:** Nishith Khandwala (Co-Founder & CEO), David Eng (Co-Founder)
- **Team size:** ~29-30 employees
- **Products:** Carebricks, Bunkerhill Contrast CAC / AVC, Bunkerhill MAC, Bunkerhill AAQ, Bunkerhill BMD
- **Notable:** Multiple first-in-class FDA clearances for opportunistic detection on routine CT (CAC, AVC, MAC, abdominal aortic diameter, bone mineral density), First AI algorithms cleared to evaluate coronary and aortic valve calcium on contrast-enhanced chest CTs, Secured a national CMS reimbursement pathway for AI cardiovascular analysis effective April 1, 2026

## Products & services

- **Carebricks** — An AI workflow platform that lets health systems create, share, and deploy AI agents for clinical and operational tasks - from actionable findings to prior authorization and referral prioritization, integrated with the EHR.
- **Bunkerhill Contrast CAC / AVC** — First-and-only FDA-cleared AI algorithms to detect and quantify coronary artery calcium and aortic valve calcium on contrast-enhanced, non-gated routine chest CT scans.
- **Bunkerhill MAC** — First FDA-authorized AI to identify mitral annular calcification, a marker of cardiovascular risk, on routine CT scans.
- **Bunkerhill AAQ** — First AI cleared to automate abdominal aortic diameter quantification on contrast and non-contrast CT.
- **Bunkerhill BMD** — FDA-cleared AI that assesses bone mineral density from spinal structures on non-contrast abdominal CT, for adults aged 30 and above, enabling opportunistic osteoporosis detection.

## Achievements

- Multiple first-in-class FDA clearances for opportunistic detection on routine CT (CAC, AVC, MAC, abdominal aortic diameter, bone mineral density)
- First AI algorithms cleared to evaluate coronary and aortic valve calcium on contrast-enhanced chest CTs
- Secured a national CMS reimbursement pathway for AI cardiovascular analysis effective April 1, 2026
- Backed by Sequoia Capital and a Y Combinator (W19) alum
- Spun out of Stanford's Center for AI in Medicine and Imaging

## Latest updates

- **2026-04** — Secured CMS reimbursement pathway and FDA clearance for the first AI algorithms to evaluate coronary and aortic valve calcium on contrast-enhanced chest CTs.
- **2026** — Announced partnership with UTMB Health to advance clinician-led AI at enterprise scale.
- **2026** — FDA clearance for Bunkerhill MAC, the first AI to detect mitral annular calcification on routine CT.
- **2026** — FDA clearance for Bunkerhill AAQ (abdominal aortic diameter) and Bunkerhill BMD (bone mineral density).

## Links

- Website: https://www.bunkerhillhealth.com
- LinkedIn: https://www.linkedin.com/company/bunkerhill-health
- Twitter/X: https://twitter.com/joinBunkerhill
- GitHub: https://github.com/bunkerhillhealth

---

Profile page: https://yespress.io/bunkerhill-health
Published by YesPress — https://yespress.io
Last updated: 2026-06-29